The Workshop Programme 2026
Registration is now open – DDI Workshop 2026
The upcoming Workshop will take place from May 31st to June 2nd, 2026.
In its 16th year, the Marbach Workshop brings together international experts to discuss current topics in drug-drug interactions. The 2026 event will update attendees on recent scientific advances and clinical applications.
The workshop starts Monday, June 1st, 2026, with Session I: DDI Implementation from Bench to Bedside. Presentations will cover challenges in applying research to clinical practice, especially for DDIs and pharmacogenomics. Academic and regulatory speakers will address knowledge gaps at drug approval, and industry experts will discuss personalized DDI management strategies.
Following a discussion at 2025 workshop with regard to publication of European Medicines Agency’s (EMA) opinion report on qualifying PBPK platforms for DDI prediction, the 2026 workshop will dedicate a session (Session II) where experts from EMA, UK’s MHRA, Certara, and J&J will reflect on review experience of regulator and software developer, and present stakeholders’ feedback on the first-of-its-kind PBPK qualification report.
On Tuesday, June 2nd, Session III covers managing complex drug interactions in vulnerable groups, including case studies from the COVID-19 pandemic and strategies for geriatric and underserved patient groups.
Session IV focuses on advancements in in vitro assays for non-CYP induction, discussing UGT induction, PBPK extrapolation, and CYP3A /UGT co-induction in DDI prediction.
Each session during the event will include interactive discussions, and participants may submit abstracts for poster presentations in Session V: Poster Session. The workshop provides an opportunity for exchanging information and networking.
The Workshop Organizers
Uwe Fuhr, MD
Amin Rostami-Hodjegan, PhD, FCP
Ping Zhao, PhD
Isabelle Ragueneau-Majlessi, MD
Dr. Wafaâ Jabrane
Workshop Programme 2026
First Announcement
Marbach DDI Workshop 2026 – First Announcement [PDF-Download | 3 MB]
| Afternoon | Individual Arrival & Check-in at Marbach Castle |
| 03:00 p.m. | Registration & Coffee |
| 04:00 p.m. | Come Together Activities – TBD Poster Session – TBD |
| 07:30 p.m. | Come Together Dinner |
| 08:00 – 09:00 a.m. | Registration & Coffee |
| 09:00 – 09:15 a.m. | Welcome Address and Introduction into the Workshop Uwe Fuhr, Amin Rostami |
| Session I | DDI Implementation from Bench to Bedside: Challenges and Opportunities Chair: Isabelle Ragueneau-Majlessi |
| 09:15 – 10:00 a.m. | KEYNOTE LECTURE: What Are the Hurdles Delaying Transition of Science from Bench to Bedside: Lessons from Pharmacogenomics and Implications for the Case of Managing DDI Sir Munir Pirmohamed, Professor, David Weatherall Chair of Medicine, University Liverpool, United Kingdom |
| 10:00 – 10:15 a.m. | Discussion |
| 10:00 – 10:45 a.m. | Addressing Drug-Drug Interaction Knowledge Gaps During Drug Development with Modeling-Informed Approach: What We Can Learn from the Past Xinning Yang, PhD, Clinical Pharmacologist, Silver Spring, Washington DC, United States of America |
| 10:45 – 10:55 a.m. | Discussion |
| 10:55 – 11:25 a.m. | Networking Over Coffee Break & Visiting Posters |
| 11:25 – 11:55 a.m. | Implementing PGx and DDI Management Programs to Support Personalized Prescription: How to Successfully Translate Scientific Mechanistic Knowledge into Clinical Practice. Houda Hachad, PhD, Aranscia Precision Medicine, United States of America |
| 11:55 – 12:05 a.m. | Discussion |
| 12:05 – 12:30 p.m. | Panel discussion |
| 12:30 – 02:00 p.m. | Networking Over Lunch |
| Session II | The EMA PBPK Model Qualification Pathway Chair: Amin Rostami |
| 02:00 – 02:30 p.m. | Model Qualification Pathway at EMA: The PBPK Case with DDI as Context of Use Efthymios Manolis, PharmD, EMA, The Netherlands |
| 02:30 – 03:00 p.m. | The Roller-Coster of Platform Qualification: The PBPK Case with DDI as Context of Use Karen Rowland Yeo, PhD, Certara, United Kingdom |
| 03:00 – 03:30 p.m. | Networking Over Coffee Break & Visiting Posters |
| 03:30 – 03:40 p.m. | Feedback on EMA Qualification Susan Cole, PhD, MHRA, United Kingdom |
| 03:40 – 03:50 p.m. | Feedback on EMA Qualification Loeckie De Zwart, PhD, J&J, Belgium |
| 03:50 – 04:00 p.m. | Reflections on Qualification Rolf Burghaus, PhD, Head Virtual Patients, Bayer AG, Germany |
| 04:00 – 04:10 p.m. | Feedback on EMA Qualification Hao Zhu, PhD, Silver Spring, Washington DC, United States of America |
| 04:10 – 05:00 p.m. | Panel Discussion |
| 07:00 p.m. | Networking Over Dinner |
| Session III | Complex DDIs Chair: Uwe Fuhr |
|---|---|
| 08:30 – 09:15 a.m. | KEYNOTE LECTURE: Complex DDIs and How They Were Managed in COVID Pandemic Eric Chan, Professor, National University of Singapore, Singapore |
| 09:15 – 09:30 a.m. | Discussion |
| 09:30 – 09:55 a.m. | Novel Strategies for the Evaluation and Management of Drug-Drug Interactions in Geriatric Patients. Zhu Zhou, PhD, The City University of New York, United States of America |
| 09:55 – 10:05 a.m. | Discussion |
| 10:05 – 10:30 a.m. | Networking Over Coffee Break & Visiting Posters |
| 10:30 – 10:55 a.m. | An Integrated Approach to Enable Efficient Management of Complex DDIs in Global Health Lisa Almond, PhD, Certara, United Kingdom |
| 10:55 – 11:05 a.m. | Discussion |
| 11:05 – 11:30 a.m. | PBPK in Antimalarial Drug Development – Managing Complex Drug Interactions in Underserved Populations Nada Abla Geiser, PhD, Director, Drug Disposition & PBPK Modelling, Medicines for Malaria Venture Medicines, Switzerland |
| 11:30 – 11:40 a.m. | Discussion |
| 11:40 – 12:00 a.m. | Panel Discussion |
| 12:00 p.m. | Networking Over Lunch |
| Session IV | In Vitro Assays for Non-CYP Induction? Chair: Ping Zhao |
| 01:30 – 01:55 p.m. | How to study UGT Induction In Vitro and Apply This as an Input for Potential Extrapolation via PBPK Diane Ramsden, PhD, Senior Director DMPK, Korro Bio, Inc., Cambridge, United States of America |
| 01:55 – 02:05 p.m. | Discussion |
| 02:05 – 02:30 p.m. | Assessing CYP3A/UGT Co-Induction and its Application for DDI Prediction Xinning Yang, PhD, Clinical Pharmacologist, Silver Spring, Washington DC, United States of America |
| 02:30 – 02:40 p.m. | Discussion |
| 02:40 – 03:05 p.m. | Scientific Aspects of PBPK Extrapolation for UGT DDIs: Are We There Yet? Mattia Berton, PhD, PharmD, F. Hoffmann-La Roche Ltd, Switzerland |
| 03:05 – 03:15 p.m. | Discussion |
| 03:15 – 03:30 p.m. | Networking Over Coffee Break & Visiting Posters |
| Session V | Poster Session Chair: Amin Rostami |
| 03:30 – 04:30 p.m. | Short Presentation & Discussion of Selected Posters |
| 04:30 – 04:45 p.m. | Concluding Remarks – Amin Rostami End of Meeting & Departure |
Last Update: 19.11.2025